MARKET

SAGE

SAGE

SAGE
NASDAQ

Real-time Quotes | Nasdaq Last Sale

31.50
+0.55
+1.78%
After Hours: 31.75 +0.25 +0.79% 17:56 03/27 EDT
OPEN
29.94
PREV CLOSE
30.95
HIGH
32.30
LOW
29.39
VOLUME
943.71K
TURNOVER
--
52 WEEK HIGH
193.56
52 WEEK LOW
25.01
MARKET CAP
1.64B
P/E (TTM)
-2.3534
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of SAGE and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 23 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average SAGE stock price target is 83.53 with a high estimate of 212.00 and a low estimate of 28.00.

EPS

SAGE News

More
  • Hedge Funds Were Buying SAGE Therapeutics Inc (SAGE) Before The Coronavirus
  • Insider Monkey · 15h ago
  • Here's Why The Best Is Yet to Come for Axsome Therapeutics
  • MotleyFool.com · 4d ago
  • An Egg Stock That Looks Tasty, Especially Now
  • Barrons.com · 03/21 01:30
  • Edited Transcript of SAGE earnings conference call or presentation 27-Feb-20 1:00pm GMT
  • Thomson Reuters StreetEvents · 03/19 22:57

Industry

Biotechnology & Medical Research
-2.43%
Pharmaceuticals & Medical Research
-0.87%

Hot Stocks

Symbol
Price
%Change

About SAGE

SAGE Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company's lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor. The Company's next-generation product candidates, SAGE-217 and SAGE-689, also target the GABAA receptor system. The Company is focused on developing drugs based on selective allosteric modulation of CNS synaptic and extrasynaptic receptors. The Company's chemistry platform is focused on the chemical scaffolds of endogenous or chemically modified synthetic neuroactive steroid compounds that are allosteric modulators of GABAA or N-Methyl-D-aspartic acid or N-Methyl-D-aspartate (NMDA) receptors.
More

Webull offers kinds of SAGE Therapeutics Inc stock information, including NASDAQ:SAGE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SAGE stock news, and many more online research tools to help you make informed decisions.